12-Jul-2019 - Agilent Technologies Inc.

Agilent to Acquire BioTek

Agilent Technologies Inc. announced it has signed a definitive agreement to acquire privately-owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion.

The transaction is expected to be completed in Agilent's fiscal fourth quarter of this year, subject to regulatory approvals and customary closing conditions. Agilent expects the acquisition will be accretive to non-GAAP earnings per share, contributing $0.02-$0.04 for fiscal year 2020, and compounding growth thereafter.

"BioTek represents a strong strategic fit with Agilent," said Mike McMullen, Agilent president and CEO. "The combination of these two companies will accelerate our multi-year growth strategy to expand our position in cell analysis. This is another example of Agilent investing in high-growth segments of the life sciences market to serve new and existing customers. Agilent is committed to continuing operations in Vermont and retaining the great team of nearly 500 employees that have been at the core of BioTek's 50-year history of excellence and success."

Expanding Portfolio and Leadership in Cell Analysis

Agilent entered the cell analysis segment in 2015 with the acquisition of Seahorse Bioscience. Agilent Seahorse XF technology was a leap in the evolution of cellular metabolism analysis, allowing researchers to better understand metabolic profiles in live cells.

In January 2018, Agilent broadened its portfolio of cell analysis solutions through the acquisition of Luxcel Biosciences.

In September 2018, Agilent differentiated its portfolio further through the acquisition of ACEA Biosciences. Upon closing, the size of Agilent's cell analysis business will be in excess of $250 million in annual revenues.

"By combining BioTek's offerings with Agilent's, we will deliver a breadth of differentiated workflows, enabling customers to obtain deeper, more reliable insights across a variety of cell analysis applications," said Jacob Thaysen, president of Agilent's Life Sciences and Applied Markets Group. "This positions Agilent well in the large and growing immuno-oncology and immunotherapy markets and expands our presence in biopharma, academia and research as customers seek to understand complex cellular environments and interactions."

Facts, background information, dossiers
  • acquisitions
  • Agilent Technologies
  • BioTek Instruments
More about Agilent
More about BioTek
  • Companies

    BMG LABTECH GmbH

    BMG LABTECH offers high-end plate reader solutions for drug discovery and HTS. The plate readers provides best sensitivity, best flexibility and reliability. The integration of these microplate readers into robotic systems is easy; especially for the robot integration in high throughput scr ... more

    Merck KGaA

    We are a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. We make a positive difference to millions of people’s lives every day. Our constant curiosity and specialist approach drive o ... more

    Analytik Jena GmbH

    Analytik Jena is a leading provider of high-end analytical measuring technology, of instruments and products in the fields of biotechnology and molecular diagnostics, as well as of high quality liquid handling and automation technologies. Its portfolio includes traditional analytical techno ... more